levofloxacin-based triple therapy — Competitive Intelligence Brief

levofloxacin-based triple therapy (levofloxacin-based triple therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoroquinolone antibiotic (in combination therapy). Area: Infectious Disease / Gastroenterology.

marketed Fluoroquinolone antibiotic (in combination therapy) Bacterial DNA gyrase and topoisomerase IV Infectious Disease / Gastroenterology Small molecule

Target snapshot

levofloxacin-based triple therapy (levofloxacin-based triple therapy) — National Taiwan University Hospital. Levofloxacin-based triple therapy combines a fluoroquinolone antibiotic with two other agents to eradicate Helicobacter pylori infection by inhibiting bacterial DNA gyrase and topoisomerase IV.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
levofloxacin-based triple therapy TARGET	levofloxacin-based triple therapy	National Taiwan University Hospital	marketed	Fluoroquinolone antibiotic (in combination therapy)	Bacterial DNA gyrase and topoisomerase IV
Third generation fluoroquinolone	Third generation fluoroquinolone	University of Roma La Sapienza	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
moxifloxacin 0.5% eye drops	moxifloxacin 0.5% eye drops	Allergan	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Cravit-based sequential therapy	Cravit-based sequential therapy	National Taiwan University Hospital	marketed	Fluoroquinolone antibiotic (as part of sequential therapy regimen)	Bacterial DNA gyrase and topoisomerase IV
Moxifloxacin 0.5% ophthalmic solution	Moxifloxacin 0.5% ophthalmic solution	Johns Hopkins University	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Vigamox Eye Drops	Vigamox Eye Drops	Merck Sharp & Dohme LLC	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Intracameral Moxifloxacin 0.1%	Intracameral Moxifloxacin 0.1%	Suzan A Rattan	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoroquinolone antibiotic (in combination therapy) class)

1. National Taiwan University Hospital · 1 drug in this class